A ADAPTIVE BIOTECHNOLOGIES COR
$14.81
| Market Cap | $2.28B |
| P/E Ratio | — |
| Forward P/E | -54.85 |
| Dividend Yield | — |
| Beta | 2.30 |
| 52W Range | $6.83 - $20.46 |
| # Hedge Funds | 2 |
| Sector | Healthcare |
| Industry | Biotechnology |
Hedge Fund Ownership
| Investor 2 | % of Portfolio Weight of this stock in the investor's portfolio | Value Total dollar value of the position | Shares Number of shares held | Activity Portfolio change type: New, Increased, Decreased, or Sold |
|---|---|---|---|---|
| Viking Global Investors Viking Global Investors | 1.29% | $487.10M | 29,993,708 | — |
| Polen Capital Management Polen Capital Management | 0.02% | $5.29M | 325,767 | Add 11.87% |
Insider Trading
| Insider Name of the company insider who made the trade 81 | Type Purchase (buy) or Sale (sell) | Shares Number of shares traded | Price Price per share at time of transaction | Value Total dollar value of the transaction | Trade Date Date the transaction was executed | Filing Date Date the SEC filing was submitted |
|---|---|---|---|---|---|---|
| RUBINSTEIN JULIEPresident and COO | Sale | 19,060 | $14.60 | $278.28K | 02 Apr 2026 | 01 Apr 2026 |
| RUBINSTEIN JULIEPresident and COO | Sale | 19,060 | $14.45 | $275.42K | 01 Apr 2026 | 01 Apr 2026 |
| Julie RubinsteinPresident and COO | Sale | 19,060 | $13.45 | $256.36K | 31 Mar 2026 | 31 Mar 2026 |
| Julie RubinsteinPresident and COO | Sale | 19,060 | $12.63 | $240.73K | 30 Mar 2026 | 31 Mar 2026 |
| Julie RubinsteinPresident and COO | Sale | 16,322 | $13.48 | $220.02K | 27 Mar 2026 | 31 Mar 2026 |
| Julie RubinsteinPresident and COO | Sale | 2,738 | $12.49 | $34.20K | 27 Mar 2026 | 31 Mar 2026 |
| RUBINSTEIN JULIEPresident and COO | Sale | 19,060 | $14.12 | $269.13K | 26 Mar 2026 | 24 Mar 2026 |
| RUBINSTEIN JULIEPresident and COO | Sale | 19,060 | $14.27 | $271.99K | 25 Mar 2026 | 24 Mar 2026 |
| RUBINSTEIN JULIEPresident and COO | Sale | 19,060 | $13.70 | $261.12K | 24 Mar 2026 | 24 Mar 2026 |
| RUBINSTEIN JULIEPresident and COO | Sale | 19,060 | $13.83 | $263.60K | 23 Mar 2026 | 19 Mar 2026 |
| RUBINSTEIN JULIEPresident and COO | Sale | 19,060 | $13.37 | $254.83K | 20 Mar 2026 | 19 Mar 2026 |
| RUBINSTEIN JULIEPresident and COO | Sale | 19,060 | $13.18 | $251.21K | 19 Mar 2026 | 19 Mar 2026 |
| RUBINSTEIN JULIEPresident and COO | Sale | 19,060 | $13.18 | $251.21K | 18 Mar 2026 | 16 Mar 2026 |
| RUBINSTEIN JULIEPresident and COO | Sale | 19,060 | $13.40 | $255.40K | 17 Mar 2026 | 16 Mar 2026 |
| RUBINSTEIN JULIEPresident and COO | Sale | 19,060 | $13.41 | $255.59K | 16 Mar 2026 | 16 Mar 2026 |
| RUBINSTEIN JULIEPresident and COO | Sale | 19,060 | $12.96 | $247.02K | 13 Mar 2026 | 13 Mar 2026 |
| RUBINSTEIN JULIEPresident and COO | Sale | 5,400 | $13.43 | $72.52K | 12 Mar 2026 | 13 Mar 2026 |
| RUBINSTEIN JULIEPresident and COO | Sale | 13,660 | $12.63 | $172.53K | 12 Mar 2026 | 13 Mar 2026 |
| RUBINSTEIN JULIEPresident and COO | Sale | 19,060 | $14.08 | $268.36K | 11 Mar 2026 | 13 Mar 2026 |
| RUBINSTEIN JULIEPresident and COO | Sale | 122,523 | $13.17 | $1.61M | 11 Mar 2026 | 13 Mar 2026 |
| GRIFFIN MICHELLE RENEE | Sale | 15,394 | $13.91 | $214.13K | 11 Mar 2026 | 13 Mar 2026 |
| PISKEL KYLEChief Financial Officer | Sale | 18,672 | $13.17 | $245.91K | 11 Mar 2026 | 13 Mar 2026 |
| BOBULSKY SUSANChief Commercial Officer, MRD | Sale | 41,338 | $13.17 | $544.42K | 11 Mar 2026 | 13 Mar 2026 |
| ROBINS HARLAN SChief Scientific Officer | Sale | 329,600 | $13.17 | $4.34M | 11 Mar 2026 | 13 Mar 2026 |
| ROBINS HARLAN SChief Scientific Officer | Sale | 140,666 | $13.17 | $1.85M | 11 Mar 2026 | 13 Mar 2026 |
| ROBINS CHAD MCEO and Chairman | Sale | 329,600 | $13.17 | $4.34M | 11 Mar 2026 | 13 Mar 2026 |
| ROBINS CHAD MCEO and Chairman | Sale | 140,567 | $13.17 | $1.85M | 11 Mar 2026 | 13 Mar 2026 |
| LO FRANCISChief People Officer | Sale | 30,593 | $14.08 | $430.75K | 11 Mar 2026 | 13 Mar 2026 |
| BENZENO SHARONChief Commercial Ofc Imm Med | Sale | 63,103 | $13.17 | $831.07K | 11 Mar 2026 | 13 Mar 2026 |
| RUBINSTEIN JULIEPresident and COO | Sale | 19,460 | $14.68 | $285.67K | 10 Mar 2026 | 06 Mar 2026 |
| RUBINSTEIN JULIEPresident and COO | Sale | 30,941 | $14.79 | $457.62K | 09 Mar 2026 | 06 Mar 2026 |
| RUBINSTEIN JULIEPresident and COO | Sale | 30,941 | $15.14 | $468.45K | 06 Mar 2026 | 06 Mar 2026 |
| LO FRANCISChief People Officer | Sale | 38,074 | $15.09 | $574.54K | 05 Mar 2026 | 05 Mar 2026 |
| RUBINSTEIN JULIEPresident and COO | Sale | 30,941 | $16.00 | $495.06K | 05 Mar 2026 | 05 Mar 2026 |
| RUBINSTEIN JULIEPresident and COO | Sale | 30,941 | $16.60 | $513.62K | 04 Mar 2026 | 05 Mar 2026 |
| RUBINSTEIN JULIEPresident and COO | Sale | 6,518 | $16.33 | $106.44K | 03 Mar 2026 | 05 Mar 2026 |
| ROBINS CHAD MCEO and Chairman | Sale | 2,380 | $16.15 | $38.44K | 03 Mar 2026 | 03 Mar 2026 |
| ROBINS CHAD MCEO and Chairman | Sale | 50,703 | $15.49 | $785.39K | 03 Mar 2026 | 03 Mar 2026 |
| GRIFFIN MICHELLE RENEE | Sale | 48,044 | $15.30 | $735.07K | 03 Mar 2026 | 05 Mar 2026 |
| RUBINSTEIN JULIEPresident and COO | Sale | 24,423 | $15.49 | $378.31K | 03 Mar 2026 | 05 Mar 2026 |
| ROBINS HARLAN SChief Scientific Officer | Sale | 14,233 | $16.52 | $235.13K | 03 Mar 2026 | 04 Mar 2026 |
| ROBINS HARLAN SChief Scientific Officer | Sale | 10,000 | $15.72 | $157.20K | 02 Mar 2026 | 04 Mar 2026 |
| ROBINS CHAD MCEO and Chairman | Sale | 289,024 | $15.82 | $4.57M | 02 Mar 2026 | 03 Mar 2026 |
| ROBINS CHAD MCEO and Chairman | Sale | 182,891 | $15.99 | $2.92M | 27 Feb 2026 | 03 Mar 2026 |
| PISKEL KYLEChief Financial Officer | Sale | 2,145 | $18.46 | $39.60K | 04 Feb 2026 | 06 Feb 2026 |
| Kyle PiskelChief Financial Officer | Sale | 2,145 | $18.46 | $39.60K | 04 Feb 2026 | 06 Feb 2026 |
| ROBINS HARLAN SChief Scientific Officer | Sale | 8,120 | $19.00 | $154.28K | 03 Feb 2026 | 04 Feb 2026 |
| Harlan S RobinsChief Scientific Officer | Sale | 8,120 | $19.00 | $154.28K | 03 Feb 2026 | 04 Feb 2026 |
| ROBINS HARLAN SChief Scientific Officer | Sale | 34,668 | $18.60 | $644.82K | 02 Feb 2026 | 04 Feb 2026 |
| ROBINS CHAD MCEO and Chairman | Sale | 124,998 | $18.44 | $2.30M | 02 Feb 2026 | 04 Feb 2026 |
| Harlan S RobinsChief Scientific Officer | Sale | 34,668 | $18.60 | $644.82K | 02 Feb 2026 | 04 Feb 2026 |
| Chad M RobinsCEO and Chairman | Sale | 124,998 | $18.44 | $2.30M | 02 Feb 2026 | 04 Feb 2026 |
| LO FRANCISChief People Officer | Sale | 79,590 | $17.73 | $1.41M | 12 Jan 2026 | 14 Jan 2026 |
| PISKEL KYLEChief Financial Officer | Sale | 4,290 | $18.00 | $77.22K | 12 Jan 2026 | 14 Jan 2026 |
| ROBINS HARLAN SChief Scientific Officer | Sale | 10,000 | $16.44 | $164.40K | 06 Jan 2026 | 08 Jan 2026 |
| ROBINS CHAD MCEO and Chairman | Sale | 124,998 | $15.59 | $1.95M | 05 Jan 2026 | 07 Jan 2026 |
| Chad M RobinsCEO and Chairman | Sale | 124,998 | $15.59 | $1.95M | 05 Jan 2026 | 07 Jan 2026 |
| LO FRANCISChief People Officer | Sale | 3,125 | $16.08 | $50.25K | 02 Jan 2026 | 06 Jan 2026 |
| Francis LOChief People Officer | Sale | 3,125 | $16.08 | $50.25K | 02 Jan 2026 | 06 Jan 2026 |
| LO FRANCISChief People Officer | Sale | 4,394 | $17.50 | $76.89K | 22 Dec 2025 | 29 Dec 2025 |
| Francis LOChief People Officer | Sale | 4,394 | $17.50 | $76.89K | 22 Dec 2025 | 29 Dec 2025 |
| LO FRANCISChief People Officer | Sale | 113,890 | $15.57 | $1.77M | 15 Dec 2025 | 17 Dec 2025 |
| HERSHBERG ROBERT | Sale | 22,968 | $16.00 | $367.49K | 10 Dec 2025 | 12 Dec 2025 |
| ROBINS HARLAN SChief Scientific Officer | Sale | 10,000 | $16.61 | $166.10K | 04 Dec 2025 | 05 Dec 2025 |
| BENZENO SHARONChief Commercial Ofc Imm Med | Sale | 12,604 | $16.85 | $212.38K | 04 Dec 2025 | 08 Dec 2025 |
| ROBINS HARLAN SChief Scientific Officer | Sale | 27,212 | $18.61 | $506.42K | 03 Dec 2025 | 05 Dec 2025 |
| ROBINS CHAD MCEO and Chairman | Sale | 124,998 | $18.94 | $2.37M | 01 Dec 2025 | 01 Dec 2025 |
| Chad M RobinsCEO and Chairman | Sale | 124,998 | $18.94 | $2.37M | 01 Dec 2025 | 01 Dec 2025 |
| PISKEL KYLEChief Financial Officer | Sale | 162,820 | $19.50 | $3.17M | 28 Nov 2025 | 02 Dec 2025 |
| Kyle PiskelChief Financial Officer | Sale | 162,820 | $19.50 | $3.17M | 28 Nov 2025 | 02 Dec 2025 |
| ROBINS CHAD MCEO and Chairman | Sale | 35,736 | $19.68 | $703.28K | 26 Nov 2025 | 01 Dec 2025 |
| Chad M RobinsCEO and Chairman | Sale | 35,736 | $19.68 | $703.28K | 26 Nov 2025 | 01 Dec 2025 |
| BENZENO SHARONChief Commercial Ofc Imm Med | Sale | 308,477 | $16.91 | $5.22M | 21 Nov 2025 | 24 Nov 2025 |
| Sharon BenzenoChief Commercial Ofc Imm Med | Sale | 308,477 | $16.91 | $5.22M | 21 Nov 2025 | 24 Nov 2025 |
| BENZENO SHARONChief Commercial Ofc Imm Med | Sale | 297,925 | $16.54 | $4.93M | 20 Nov 2025 | 24 Nov 2025 |
| Sharon BenzenoChief Commercial Ofc Imm Med | Sale | 297,925 | $16.54 | $4.93M | 20 Nov 2025 | 24 Nov 2025 |
| PISKEL KYLEChief Financial Officer | Sale | 238 | $14.05 | $3.34K | 17 Nov 2025 | 18 Nov 2025 |
| ROBINS CHAD MCEO and Chairman | Sale | 1,867 | $15.00 | $28.00K | 12 Nov 2025 | 12 Nov 2025 |
| ROBINS CHAD MCEO and Chairman | Sale | 1,237 | $14.57 | $18.02K | 11 Nov 2025 | 12 Nov 2025 |
| ROBINS CHAD MCEO and Chairman | Sale | 86,161 | $14.73 | $1.27M | 10 Nov 2025 | 12 Nov 2025 |
| ROBINS HARLAN SChief Scientific Officer | Sale | 10,000 | $14.82 | $148.20K | 10 Nov 2025 | 12 Nov 2025 |
Frequently Asked Questions
What is ADPT stock price today?
ADAPTIVE BIOTECHNOLOGIES COR (ADPT) is currently trading at $14.81. The stock has a 52-week range of $6.83 to $20.46 and a market capitalization of $2.28B.
Is ADPT a good stock to buy in 2026?
ADAPTIVE BIOTECHNOLOGIES COR has a P/E ratio of N/A (forward P/E: N/A), a dividend yield of none, and 1-year performance of +99.9%. 2 hedge funds hold this stock. Review the fundamentals and ownership data above to make an informed decision.
Are insiders buying or selling ADPT stock?
There have been 81 insider transactions for ADPT in recent months. Insider buys can signal management confidence, while sales may reflect diversification or personal financial planning. Check the Insider Trading section above for details.
How has ADPT stock performed over the past year?
ADAPTIVE BIOTECHNOLOGIES COR (ADPT) has returned +99.9% over the past 12 months. The stock traded between $6.83 and $20.46 during this period, and is currently at $14.81.
Which hedge funds own ADPT (ADAPTIVE BIOTECHNOLOGIES COR)?
2 tracked hedge funds currently hold ADPT in their portfolios as of the latest 13F filings. See the ownership table above for the complete list.
What is ADPT's market cap and valuation?
ADAPTIVE BIOTECHNOLOGIES COR (ADPT) has a market capitalization of $2.28B. The trailing P/E ratio is N/A and forward P/E is N/A. The stock is classified in the Healthcare sector.
What is ADPT's revenue and profitability?
ADAPTIVE BIOTECHNOLOGIES COR reported revenue of $276.98M with net income of N/A and a profit margin of N/A. The stock has a beta of 2.30.
What sector is ADPT in and who are its biggest institutional holders?
ADAPTIVE BIOTECHNOLOGIES COR (ADPT) operates in the Healthcare sector. It is held by 2 tracked hedge funds. See the ownership table above for the complete list.